<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873103</url>
  </required_header>
  <id_info>
    <org_study_id>BSMO 2014-2</org_study_id>
    <nct_id>NCT03873103</nct_id>
  </id_info>
  <brief_title>The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment</brief_title>
  <official_title>The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment - Precision 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Belgian Society of Medical Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Belgian Society of Medical Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRECISION 1 will enroll patients with metastatic solid tumors. The local PI will verify if
      the candidate patient fits the inclusion/ exclusion criteria.

      The participant will sign the PRECISION 1 informed consent. NGS data will be collected from
      local panel testing on DNA extracted from tissue samples or plasma.

      Data will be collected from further molecular testing performed at the different
      laboratories: select rearrangements (fusion genes and translocations) by RT PCR, FISH or NGS;
      copy number variations of selected genes via the NGS platform (if possible) or using FISH or
      other technologies such as SNP arrays in case the NGS technology is incapable of giving this
      information.

      Results will be stored in the Precision Belgium section of the Healthdata database.

      Data on germline variants will also be collected in the Healthdata database whenever this
      information is available.

      The cooperating clinical investigator will decide with the patient the treatment strategy,
      -guided by the best interest of the patient and the availability of respective options :

        -  &quot; Empirical &quot; available approved treatment (for example chemotherapy, immunotherapy)

        -  Genotype-driven standard of care

        -  Inclusion in a genotype-matched clinical trial (includes signing of trial-specific IC)

        -  Inclusion in PRECISION 2 if options 2/3 not available. Irrespective of treatment choice,
           the patient will be followed by the collaborating clinician and will have follow-up data
           collected every 6 months for determination of disease status and survival endpoints.

      Clinical data will be collected and stored in the Healthdata database. Genomic data (somatic
      and germline whenever available) and clinical data (tumor type and stage, number of previous
      lines, treatment choice, response rate, PFS on chosen and previous treatments, …) will be
      uploaded on the Healthdata platform and can be consulted via password-protected web access by
      the local PI at each participating center. European regulation protecting patient privacy
      will apply (&quot;GDPR&quot;).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of patients with &quot;actionable&quot; driven mutations.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients enrolled in genomics-driven clinical trials and in the PRECISION 2 clinical trial.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical benefit rate as defined by survival and/or objective response rate and rate of stable disease lasting more than 6 months with genomics-driven therapy in non-approved indications</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Metastatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        1000 patients with metastatic solid tumors that are eligible for systemic therapy will be
        recruited at 7 Belgian academic centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic solid tumors that are candidates for systemic therapy (early
             lines are preferred).

          -  Patient showing an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤
             2.

          -  Patients able to provide written informed consent prior to enrollment into a
             subsequent clinical trial.

          -  Patients agrees to provide NGS data (somatic and/or germline) as well as clinical data
             baseline and during follow-up.

        Exclusion Criteria:

          -  Life expectancy of less than 12 weeks.

          -  Inability to comply with protocol procedures.

          -  Known presence of severe hematopoietic, renal, and/or hepatic dysfunction (according
             to the local PI).

          -  Targeted gene sequencing on DNA extracted from decalcified bone biopsies is not
             accepted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Aftimos, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Jules Bordet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gordana Raicevic Toungouz, PhD</last_name>
    <phone>003226425490</phone>
    <email>gordana.raicevictoungouz@sciensano.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dirk Schrijvers, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luc Dirix, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charis Loos</last_name>
    </contact>
    <investigator>
      <last_name>Wim Demey, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Kim Bergström</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Aftimos, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Cappoen</last_name>
    </contact>
    <investigator>
      <last_name>Lore Decoster, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Les Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Papier</last_name>
    </contact>
    <investigator>
      <last_name>François Duhoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marika Rasschaert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lore Vansteelant</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie Rottey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène Schroeder</last_name>
      <email>hschroeder@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Joelle Collignon, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Willem Lybaert, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

